OncoPharm

Recent FDA approvals of drugs like enforte map, pembrolizumab, and nivoleumab for metastatic urothelial cancer. Positive outcomes seen in the EV302 study with Fort Tumab Vadot and Pembrolizumab combination therapy. Exploration of new treatments in bladder cancer, including immune checkpoint inhibitors. Revolutionizing treatment for metastatic bladder cancer with high complete response rates and improved overall survival compared to traditional chemotherapy.

Two nice studies have been recently published in the supportive care realm. SPARED asks if we can omit dexamethasone on days 2-4 following cisplatin-based chemotherapy. D-TORCH asks if topical diclofenac can prevent capecitabine-induced hand-foot syndrome. SPARED: https://doi.org/10.1038/s41416-023-02493-7 D-TORCH: https://doi.org/10.1200/JCO.23.01730

An exciting new cellular therapy, lifileucel, is approved for metastatic melanoma. The FLAURA2 trial of osimertinib + chemotherapy has led to an FDA approval, but questions remain about a possible new standard of care. And a few minor updates on tepotinib.

Discover groundbreaking updates in oncology, starting with a potential new first-line treatment for metastatic pancreatic cancer, combining nalirifox's efficacy against previous standards. Dive into the positive results of the POUT trial, revealing significant improvements in disease-free and overall survival for upper tract urothelial cancer. Lastly, explore the critical drug interactions between ivosidenib and azole antifungals, highlighting the need for monitoring and adjustments to ensure therapeutic levels.

You know about small cell lung cancer, but let's talk about small cell carcinoma of the prostate.

In oncology we are always asking questions about which treatment option is best. And that focus on the next best treatment may prevent us from rethinking some fundamentals of current practice. Three recent studies illustrate this and made me ask: Do we need a Port or PICC for every testicular cancer patient? Study: https://doi.org/10.1200/OP.23.00580 Editorial: https://doi.org/10.1200/OP.23.00730 Is vaginal estrogen safe if breast cancer patients? Study: https://jamanetwork.com/journals/jamaoncology/article-abstract/2811413 Does paclitaxel work differently than we always thought? Study: https://doi.org/10.1371/journal.pbio.3002339

...on FDA approvals for belzutifan for RCC, pembrolizumab + cisplatin/RT for cervical cancer, erdafitinib (FGFR3 alterations only) for bladder cancer. Plus, early morning ICIs (https://doi.org/10.1016/j.ejca.2024.113571) & FLAG-Ida-GO in AML from NCRI AML 19 (https://doi.org/10.1200/JCO.23.00943)

Special guest Ryan Beechinor joins the pod to discuss his recent paper on the obstacles in the development of generic lenalidomide. It's a fantastic read, and this episode will be a fantastic listen! Link: https://doi.org/10.1016/j.jcpo.2023.100446

Dive into the fascinating world of lenalidomide, a key player in treating hematologic cancers like multiple myeloma. Discover its unique mechanism of action and essential dosing guidelines. The discussion covers crucial safety precautions and the role of the REMS program in patient monitoring. Tune in for insights on the balance between effectiveness and potential toxicity.

A Holiday Tradition returns as we review 14 new OncoPharm drugs approved this past year and ask Keep, Re-Gift, or Return.